Nordic Life Science 1
TOP STORIES MER G E BIOVIAN and 3P Biopharmaceuti
cals join forces T HE COMBINED GROUP, named 3PBIOVIAN, will become one of the main independent European bio-CDMOs, with gross sales above EUR 75 million. Their common shareholder, Keensight Capital will continue to help the new Group strengthen its position at a global level and ERES IV, advised by Elyan Partners, and Sodena, will each continue as minority shareholders alongside Keensight, maintaining their investment in the Group. 3PBIOVIAN will leverage its manufacturing sites in PamplonaNoáin (Spain) and Turku (Finland) as well as its commercial office in Boston, MA (United States). Dámaso Molero Sánchez (former 3P CEO) will serve as Group CEO supported by Deputy CEO Antti Nieminen (former Biovian CEO), Heidi Suuronen as CFO and Elena Erroba as CCO (Chief Commercial Officer). NLS Antti Nieminen, Deputy CEO, 3PBIOVIAN